Virscio has been distinguished as the Top Preclinical Research Company of 2023 by Life Sciences Review! This accolade is a testament to our unwavering commitment to pioneer breakthrough therapeutic modalities for challenging diseases such as Alzheimer’s, dry-age-related macular degeneration (AMD), and other neurodegenerative conditions.
In addition to the award, Life Sciences Review sat down with Virscio’s CEO and Chief Scientific Officer, Matthew Lawrence, to discuss Virscio’s mission, innovative approaches, and the future we envision in the therapeutic development space.
Read the full article at Life Science Review!